Resistance Of The Mutant Oncogenes - amazonia.fiocruz.br

Resistance Of The Mutant Oncogenes - commit

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page. Cancer , 30 Jan , 9 : DOI: Free to read. Owonikoko, Suresh S. Ramalingam and Shi-Yong Sun. Therefore, effective strategies that can overcome osimertinib acquired resistance are urgently needed. Our efforts in this direction have identified LBH panobinostat , a clinically used HDAC inhibitor, as a potential agent in overcoming osimertinib resistance. Cell growth and apoptosis in vitro were evaluated by measuring cell numbers and colony formation and by detecting annexin V-positive cells and protein cleavage, respectively. Resistance Of The Mutant Oncogenes

Resistance Of The Mutant Oncogenes - similar it

The EGF receptor family as targets for cancer therapy. Dearden S et al. Nonetheless, it is still unclear why clinical outcomes vary among patients with identical EGFR mutations. A number of genetic drivers of tumour growth have been identified in patients with non-small cell lung cancer NSCLC , including mutations in the epidermal growth factor receptor EGFR gene. Epidemiol Biomarkers Prev ; — Tumor response rates to second-line EGFR TKI have been inconsistent, which could potentially be explained by the impact of first-line chemotherapy on the abundance of tumor cells with activating EGFR mutations. DOI: Kris MG et al. Institutions DOI: Analysis of tumor specimens at the time of acquired resistance to.

These metrics are regularly updated to reflect usage leading up to the last few days. Citations are the number of other articles citing this article, calculated by Crossref and updated daily.

Find more information about Crossref citation counts. The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online.

Clicking on the donut icon will load a page at altmetric. Find more information on the Altmetric Attention Score and how the score is calculated.

Oncogenic mutations in the KRAS gene are well-established drivers of cancer. Inhibition of KRAS downstream signaling results in a system-wide down-modulation of the respective targets, raising concerns about systemic cell toxicity. Figure 1.

Mutated nucleotides are in red. Non-Watson—Crick base pairings i.

Cells were analyzed 24 h post transfection, and qPCR was run in technical triplicate. Results were normalized to NC siR transfection. Results in the top half above the horizontal dotted line indicate poor knockdown efficacy of mutant KRAS. Lead siRs appear in the bottom right quadrant and demonstrate potent mutant inhibition and optimal WT sparing. Error bars represent standard error of the mean. Figure 2. Thirteen technical replicates were run for WT and 6—7 replicates for each mutant. Figure 3.

Results are shown 24 h post transfection and are normalized to NC siR transfection. IC 50 values for siR treatment of each cell line are shown. Figure 4. Cells were analyzed 36 h post transfection. Cells were quantified after 7 days of growth.

Introduction

Samples were run in at least triplicate, and cell counts are normalized to NC. Such files may be downloaded by article Thw research use if there is a public use license linked to the relevant article, that license may permit other uses. The authors declare the following competing financial interest s : S. More by Bjoern Papke. EnFuego Therapeutics, Inc. More by Salma H. More by Anne Y. More by Christina Gutierrez-Ford. More by Hayden Huggins. More by Pradeep S.]